Rani Therapeutics closes private placement of 42.6M shares and warrants; board changes

Rani Therapeutics Holdings, Inc.

Closed private placement of 42,633,337 shares of Class A common stock, warrants to purchase 125,000,004 shares, and pre-funded warrants for 82,366,667 shares.
Post-closing shares outstanding: 97,541,221.
Directors Andrew Farquharson and Maulik Nanavaty resigned effective closing; no disagreement cited.
Abraham Bassan (Samsara BioCapital) and Vasudev Bailey (Anomaly Ventures) appointed as directors.
Samsara and Anomaly each have board designation rights while holding at least 25% of securities issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.